Arthrex, the Naples-based giant known for its sports med dominance, is making a bold leap into total joints by acquiring UK-based Corin Group for $330M.
This deal has been the talk of the industry whisper network for months, and now it's confirmed as I am hearing the internal announcement from employees. No official press release yet, but the implications are huge—Arthrex is positioning itself to challenge the big players in hips, knees, and beyond.
Details of Acquisition
The acquisition closed at around $330M, a figure that's notably less than Corin's outstanding debt of over $360M, much of it self-financed by its owners. This makes it feel like a fire sale, especially considering that just four years ago, Arthrex reportedly offered $600M, only for Corin's leadership to walk away chasing a $1 billion valuation. Corin's global sales were hovering ~$100M (breakdowns is ~$40M in the U.S., ~$30M in Australia, and ~$30M Europe (mostly UK). The deal hands Arthrex a ready-made portfolio of implants, robotics, and tech, skipping years of internal development.
Reasons for Acquisition - Arthrex Wants to Expand into Joints Quickly and Corin is Laden with Debt and Has No Way Out
Arthrex's mo...
